elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Chronic lymphocytic leukemia
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Chronic lymphocytic leukemia
RIS
0.001
(Research Intensity Score)
Papers
203
Top papers
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
2022 · 239 citations
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
2019 · 743 citations
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
2019 · 179 citations
The cure of leukemia through the optimist's prism
2021 · 67 citations
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
2020 · 87 citations
Newest papers
The significance of galectin-9 and T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) in patients with chronic lymphocytic leukemia: The role of immune evasion
2026
Late-Onset Episodic Weakness With Hyperkalemia Suggestive of Hyperkalemic Periodic Paralysis
2026
CD37 is a promising molecular target for CAR-T cells in chronic lymphocytic leukemia
2026
Therapeutic potential of antisense oligonucleotides in hematological malignancies
2026
Radiometabolic Therapy in Lymphoma: From Radioimmunotherapy to Emerging Theranostic and Combination Strategies
2026
A sample from the 100 top papers behind Chronic lymphocytic leukemia.
Create a free account to browse them all →
Chronic lymphocytic leukemia's history
Research intensity over time
Explore Chronic lymphocytic leukemia's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Chronic lymphocytic leukemia's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link